B. Riley analyst Bryan Maher lowered the firm’s price target on Alerislife to $1.50 from $2 and keeps a Neutral rating on the shares following the "mixed" Q3 results.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALR: